Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.37% | 18.64% | 18.15% | -31.95% | -3.70% |
| Total Depreciation and Amortization | 0.44% | 18.18% | -25.71% | 7.54% | -21.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.53% | -12.20% | 253.15% | 134.66% | 118.37% |
| Change in Net Operating Assets | 73.77% | 13.23% | -121.67% | 1,914.26% | 741.22% |
| Cash from Operations | 12.66% | 19.22% | -58.21% | 28.91% | 10.05% |
| Capital Expenditure | -- | -- | 81.70% | 79.26% | -232.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 81.70% | 79.26% | -232.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.97% | -3.00% | -25.00% | -23.08% | 36.89% |
| Issuance of Common Stock | 1.59% | 72.62% | 1,157.14% | -86.78% | 30.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -262.55% | -39.05% | 55.53% | -190.08% | -84.51% |
| Cash from Financing | -5.38% | 72.05% | 1,981.15% | -108.79% | 30.16% |
| Foreign Exchange rate Adjustments | -1,837.50% | -103.53% | 488.45% | -187.65% | -65.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.91% | 82.95% | 32.18% | -10.86% | 11.79% |